Can-Fite BioPharma Ltd. (CANF)
USD 1.53
(9.44%)
USD 1.53
(9.44%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.63 Million USD | 24.96% |
| 2022 | -10.17 Million USD | 19.36% |
| 2021 | -12.61 Million USD | 12.66% |
| 2020 | -14.44 Million USD | -14.4% |
| 2019 | -12.62 Million USD | -92.13% |
| 2018 | -6.57 Million USD | -3.66% |
| 2017 | -6.33 Million USD | 23.23% |
| 2016 | -8.25 Million USD | -32.26% |
| 2015 | -6.24 Million USD | -2.38% |
| 2014 | -6.09 Million USD | 27.21% |
| 2013 | -8.37 Million USD | -49.93% |
| 2012 | -5.58 Million USD | 16.6% |
| 2011 | -6.69 Million USD | -82.18% |
| 2010 | -3.67 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.97 Million USD | 0.0% |
| 2024 Q1 | -1.97 Million USD | -19.76% |
| 2023 Q4 | -1.65 Million USD | 6.24% |
| 2023 Q2 | -1.67 Million USD | 34.51% |
| 2023 FY | -7.63 Million USD | 25.42% |
| 2023 Q1 | -2.55 Million USD | 15.53% |
| 2023 Q3 | -1.76 Million USD | -5.51% |
| 2022 Q4 | -3.01 Million USD | -19.38% |
| 2022 Q1 | -2.43 Million USD | 40.89% |
| 2022 Q2 | -2.19 Million USD | 9.98% |
| 2022 Q3 | -2.52 Million USD | -15.43% |
| 2022 FY | -10.23 Million USD | 18.73% |
| 2021 Q4 | -4.11 Million USD | -21.12% |
| 2021 FY | -12.59 Million USD | 14.93% |
| 2021 Q1 | -1.87 Million USD | 48.31% |
| 2021 Q2 | -3.21 Million USD | -71.41% |
| 2021 Q3 | -3.4 Million USD | -5.62% |
| 2020 Q3 | -2.57 Million USD | 33.86% |
| 2020 Q4 | -3.63 Million USD | -41.09% |
| 2020 Q1 | -4.34 Million USD | 9.24% |
| 2020 FY | -14.8 Million USD | -13.44% |
| 2020 Q2 | -3.89 Million USD | 10.34% |
| 2019 Q1 | -1.83 Million USD | 46.57% |
| 2019 FY | -13.05 Million USD | -98.63% |
| 2019 Q4 | -4.78 Million USD | -62.28% |
| 2019 Q2 | -3.06 Million USD | -67.09% |
| 2019 Q3 | -2.94 Million USD | 3.69% |
| 2018 Q4 | -3.42 Million USD | -1837.29% |
| 2018 FY | -6.57 Million USD | -32.25% |
| 2018 Q2 | -1.24 Million USD | 27.72% |
| 2018 Q3 | -177 Thousand USD | 85.77% |
| 2018 Q1 | -1.72 Million USD | 27.61% |
| 2017 Q2 | -2.12 Million USD | -65.81% |
| 2017 Q3 | -541.39 Thousand USD | 74.57% |
| 2017 Q1 | -1.28 Million USD | 60.42% |
| 2017 Q4 | -2.37 Million USD | -339.14% |
| 2017 FY | -4.96 Million USD | 27.96% |
| 2016 Q2 | -1.4 Million USD | 8.48% |
| 2016 FY | -6.89 Million USD | -43.79% |
| 2016 Q3 | -2.16 Million USD | -54.09% |
| 2016 Q4 | -3.24 Million USD | -49.99% |
| 2016 Q1 | -1.53 Million USD | -604.3% |
| 2015 Q2 | -1.73 Million USD | -407.21% |
| 2015 Q4 | 304.11 Thousand USD | 109.93% |
| 2015 Q3 | -3.06 Million USD | -76.81% |
| 2015 FY | -4.79 Million USD | 21.38% |
| 2015 Q1 | -341.62 Thousand USD | 81.99% |
| 2014 Q2 | -1.74 Million USD | -1.12% |
| 2014 Q3 | -1.18 Million USD | 32.28% |
| 2014 FY | -6.1 Million USD | 26.85% |
| 2014 Q1 | -1.72 Million USD | 45.75% |
| 2014 Q4 | -1.89 Million USD | -60.41% |
| 2013 Q2 | -1.56 Million USD | 23.44% |
| 2013 Q4 | -3.18 Million USD | -129.68% |
| 2013 Q3 | -1.38 Million USD | 11.32% |
| 2013 Q1 | -2.04 Million USD | -24.39% |
| 2013 FY | -8.34 Million USD | -49.68% |
| 2012 Q2 | -1.22 Million USD | -21.66% |
| 2012 Q1 | -1 Million USD | 69.92% |
| 2012 Q4 | -1.64 Million USD | -2.15% |
| 2012 Q3 | -1.6 Million USD | -31.65% |
| 2012 FY | -5.57 Million USD | 16.82% |
| 2011 Q2 | -1.23 Million USD | 13.18% |
| 2011 Q4 | -3.33 Million USD | -271.36% |
| 2011 Q3 | -898.05 Thousand USD | 27.5% |
| 2011 FY | -6.69 Million USD | -82.18% |
| 2011 Q1 | -1.42 Million USD | -22.23% |
| 2010 Q3 | -969.94 Thousand USD | 0.0% |
| 2010 Q4 | -1.16 Million USD | -20.34% |
| 2010 FY | -3.67 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -28.96 Million USD | 73.641% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | 11.562% |
| Armata Pharmaceuticals, Inc. | -69.04 Million USD | 88.943% |
| Actinium Pharmaceuticals, Inc. | -48.81 Million USD | 84.362% |
| Azitra, Inc. | -11.28 Million USD | 32.345% |
| Chromocell Therapeutics Corporation | -7.38 Million USD | -3.431% |
| Calidi Biotherapeutics, Inc. | -29.21 Million USD | 73.87% |
| CEL-SCI Corporation | -32.36 Million USD | 76.413% |
| iBio, Inc. | -24.9 Million USD | 69.35% |
| Lineage Cell Therapeutics, Inc. | -21.48 Million USD | 64.47% |
| MAIA Biotechnology, Inc. | -19.77 Million USD | 61.392% |
| Matinas BioPharma Holdings, Inc. | -22.94 Million USD | 66.725% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 49.701% |
| NovaBay Pharmaceuticals, Inc. | -9.64 Million USD | 20.809% |
| NanoViricides, Inc. | -8.29 Million USD | 7.959% |
| Oragenics, Inc. | -20.65 Million USD | 63.042% |
| BiomX Inc. | -26.16 Million USD | 70.828% |
| BiomX Inc. | -26.16 Million USD | 70.828% |
| Protalix BioTherapeutics, Inc. | 8.31 Million USD | 191.843% |
| Palatin Technologies, Inc. | -29.73 Million USD | 74.328% |
| Scorpius Holdings, Inc. | -45.21 Million USD | 83.117% |
| Theriva Biologics, Inc. | -18.34 Million USD | 58.396% |